Could a diabetes drug shield psoriatic arthritis patients from heart disease?

NCT ID NCT07251556

First seen Dec 10, 2025 · Last updated May 14, 2026 · Updated 21 times

Summary

This study looks at whether semaglutide, a drug used for diabetes, can slow down artery hardening in people with psoriatic arthritis who do not have diabetes. Psoriatic arthritis raises the risk of heart problems, and this drug may help by reducing inflammation and improving metabolism. About 40 participants will be randomly assigned to receive semaglutide or standard care, and their artery health will be checked with ultrasound over 24 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIASIS ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

Explore the condition pages connected to this study.